Existing data indicate that anti-Gal-1 strategies, like inhibitors or monoclonal antibodies, exhibit anti-proliferative and anti-angiogenic effects across multiple tumor types, underscoring their potential in countering Gal-1-induced immunosuppression in pancreatic tumors [66,161]. The gene discussed is LGALS1; the disease is neoplasm.